FIELD: medicine.
SUBSTANCE: essence of invention includes selection of sample for testing from area of malignant affection in patient, suffering from cancer of large intestine, selection of control sample, measurement of the level of one or several genetic markers, selected from the group, comparison of measured levels in experimental samples with control ones. Reducing of levels of one or several genetic markers in comparison with control sample, indicates increased resistance to docetaxel. Also described are sets which allow to predict or realise monitoring of patient's response to docetaxel.
EFFECT: identification of genetic markers, by which it is possible to realise patient's response to chemical therapy by docetaxel.
18 cl, 9 ex, 3 tbl, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN (SIRT) | 2011 |
|
RU2693462C2 |
| MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES WITH INCREASED CYTOTOXICITY | 2016 |
|
RU2772348C2 |
| CELL THERAPY BASED ON IMPROVED NATURAL KILLER CELLS | 2017 |
|
RU2776890C2 |
| NOVEL PEPTIDES AND PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND OTHER CANCERS | 2016 |
|
RU2723092C2 |
| CELL BASED QUALITY CONTROL BIOASSAYS FOR NUTRICEUTICAL AND MEDICINAL PRODUCTS | 2013 |
|
RU2662358C2 |
| POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER | 2012 |
|
RU2623161C2 |
| 3'-UTR SEQUENCES FOR RNA STABILIZATION | 2016 |
|
RU2783165C1 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| METHODS FOR PREDICTING PROSTATE CANCER | 2016 |
|
RU2760577C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
